![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.onclive.com/view/avutometinib-defactinib-combo-generates-early-efficacy-signals-in-low-grade-serous-ovarian-cancer
https://www.icr.ac.uk/news-archive/drug-combination-shows-promise-in-treatment-resistant-advanced-ovarian-cancer
https://www.businesswire.com/news/home/20201130005327/en/Verastem-Oncology-Initiates-Phase-2-Registration-Directed-Trial-of-VS-6766-and-Defactinib-in-Recurrent-Low-Grade-Serous-Ovarian-Cancer
https://www.businesswire.com/news/home/20200622005650/en/Verastem-Oncology-Announces-Presentation-Preclinical-Data-Supporting
https://www.nasdaq.com/article/whats-in-store-for-verastem-vstm-this-earnings-season-cm1046217